Onconetix Details New CEO's Employment Terms and Executive Compensation Adjustments
Summary
Onconetix filed an amended 8-K to include the employment agreement for its new CEO, David White, detailing his $21,700 monthly salary and disclosing significant compensation reductions for other executives.
Key Events
-
CEO Employment Agreement Filed
The employment agreement for newly appointed CEO David White, effective March 18, 2026, was filed as an exhibit, detailing a monthly base salary of $21,700.
-
Executive Compensation Reductions
In connection with the CEO's appointment, the monthly compensation for Interim CFO Karina Fedasz was reduced by $5,000 and for Lead Independent Director Andrew Oakley by $26,000, effective March 18, 2026.
-
Reiteration of Leadership Changes
The filing reiterates the appointment of David White as CEO and Sammy Dorf to the Board, and the resignation of Timothy Ramdeen, previously announced on March 24, 2026.
Analysis
This amended 8-K provides the specific employment agreement for newly appointed CEO David White, detailing his monthly base salary of $21,700. Crucially, it also discloses related compensation reductions for Interim CFO Karina Fedasz ($5,000/month) and Lead Independent Director Andrew Oakley ($26,000/month), effective with Mr. White's appointment. These financial details were omitted from the initial 8-K announcing the leadership changes and are material for a company facing 'going concern' issues, offering transparency into the new leadership's cost structure.
At the time of this filing, ONCO was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $2.20 to $74.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.